T cell epitope: Friend or Foe? Immunogenicity of biologics in context

Advanced Drug Delivery Reviews

Volumn 61, Issue 11, 2009, Pages 965-976

  Weber, Constanze A ^a   Mehta, Preema J ^a   Ardito, Matt ^a   Moise, Lenny ^a,b   Martin, Bill ^a   De Groot, Anne S ^a,b,c  

^a EpiVax   (United States)

^b UNIVERSITY OF RHODE ISLAND   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

Anti drug antibody; Antibodies; Antigen; Antigen presentation; Immunoinformatics; MHC; T effector cells; T lymphocyte antigens; T regulatory cells; Tolerance

Indexed keywords

ANTI-DRUG ANTIBODY; ANTIGEN PRESENTATION; IMMUNOINFORMATICS; MHC; T EFFECTOR CELLS; T LYMPHOCYTE ANTIGENS; T REGULATORY CELLS; TOLERANCE;

ANTIBODIES; ANTIGENS; CYTOLOGY; POLYPEPTIDES;

CELL MEMBRANES;

ADALIMUMAB; ALEMTUZUMAB; DRUG ANTIBODY; EPITOPE; INFLUENZA VACCINE; LIVE VACCINE; MACROGOL; RITUXIMAB; T LYMPHOCYTE ANTIGEN;

ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; AUTOIMMUNITY; B LYMPHOCYTE; BIOINFORMATICS; CELL STIMULATION; COMPUTER MODEL; EFFECTOR CELL; EPITOPE MAPPING; HELPER CELL; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PREDICTION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; VALIDATION STUDY;

ANIMALS; B-LYMPHOCYTES; BIOLOGICAL PRODUCTS; EPITOPE MAPPING; EPITOPES, T-LYMPHOCYTE; HUMANS; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY;

EID: 70349470975     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2009.07.001     Document Type: Review

References (95)

1. De Groot A.S., and Scott D.W. Immunogenicity of protein therapeutics. Trends. Immunol. 28 (2007) 482-490
2. Zubler R.H. Naive and memory B cells in T-cell-dependent and T-independent responses. Springer. Semin. Immunopathol. 23 (2001) 405-419
3. Koren E., Zuckerman L.A., and Mire-Sluis A.R. Immune responses to therapeutic proteins in humans- clinical significance, assessment and prediction. Curr. Pharm. Biotechnol. 3 (2002) 349-360
4. Casadevall N., Nataf J., Viron B., Kolta A., Kiladjian J.J., Martin-Dupont P., Michaud P., Papo T., Ugo V., Teyssandier I., Varet B., and Mayeux P. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med. 346 (2002) 469-475
5. Koren E., Smith H.W., Shores E., Shankar G., Finco-Kent D., Rup B., Barrett Y.C., Devanarayan V., Gorovits B., Gupta S., Parish T., Quarmby V., Moxness M., Swanson S.J., Taniguchi G., Zuckerman L.A., Stebbins C.C., and Mire-Sluis A. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J. Immunol. Methods 333 (2008) 1-9
6. De Groot A.S., and Martin W. Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics. Clin. Immunol. 131 (2009) 189-201
7. Southwood S., Sidney J., Kondo A., del Guercio M.F., Appella E., Hoffman S., Kubo R.T., Chesnut R.W., Grey H.M., and Sette A. Several common HLA-DR types share largely overlapping peptide binding repertoires. J. Immunol. 160 (1998) 3363-3373
8. De Groot A.S., Rayner J., and Martin W. Modelling the immunogenicity of therapeutic proteins using T cell epitope mapping. Dev. Biol. (Basel) 112 (2003) 71-80
9. Reveille J.D. The genetic basis of autoantibody production. Autoimmun. Rev. 5 (2006) 389-398
10. - T cell expansion is essential for the development of arthritis in autoimmune K/BxN mice. J. Immunol. 182 (2009) 4649-4656
11. Liu G.Y., Fairchild P.J., Smith R.M., Prowle J.R., Kioussis D., and Wraith D.C. Low avidity recognition of self-antigen by T cells permits escape from central tolerance. Immunity 3 (1995) 407-415
12. Bouneaud C., Kourilsky P., and Bousso P. Impact of negative selection on the T cell repertoire reactive to a self-peptide: a large fraction of T cell clones escapes clonal deletion. Immunity 13 (2000) 829-840
13. Kyewski B., and Derbinski J. Self-representation in the thymus: an extended view. Nat. Rev., Immunol. 4 (2004) 688-698
14. Knip M., and Siljander H. Autoimmune mechanisms in type 1 diabetes. Autoimmun. Rev. 7 (2008) 550-557
15. VanderBorght A., Geusens P., Raus J., and Stinissen P. The autoimmune pathogenesis of rheumatoid arthritis: role of autoreactive T cells and new immunotherapies. Semin. Arthritis Rheum. 31 (2001) 160-175
16. McFarland H.F., and Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat. Immunol. 8 (2007) 913-919
17. Matzinger P. The danger model: a renewed sense of self. Science 296 (2002) 301-305
18. Boucher A., Desforges M., Duquette P., and Talbot P.J. Long-term human coronavirus-myelin cross-reactive T-cell clones derived from multiple sclerosis patients. Clin. Immunol. 123 (2007) 258-267
19. Steere A.C., Klitz W., Drouin E.E., Falk B.A., Kwok W.W., Nepom G.T., and Baxter-Lowe L.A. Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide. J. Exp. Med. 203 (2006) 961-971
20. Page K.R., Scott A.L., and Manabe Y.C. The expanding realm of heterologous immunity: friend or foe?. Cell. Microbiol. 8 (2006) 185-196
21. Zubler R.H. Naive and memory B cells in T-cell-dependent and T-independent responses, Springer. Semin. Immunopathol. 23 (2001) 405-419
22. Miyake K. Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Semin. Immunol. 19 (2007) 3-10
23. Purcell A.W., McCluskey J., and Rossjohn J. More than one reason to rethink the use of peptides in vaccine design. Nat. Rev., Drug Discov. 6 (2007) 404-414
24. Takahashi H., Kuwana M., and Amagai M. A single helper T cell clone is sufficient to commit polyclonal naive B cells to produce pathogenic IgG in experimental pemphigus vulgaris. J. Immunol. 182 (2009) 1740-1745
25. Wilson C.B., Rowell E., and Sekimata M. Epigenetic control of T-helper-cell differentiation. Nat. Rev., Immunol. 9 (2009) 91-105
26. Lohr J., Knoechel B., Caretto D., and Abbas A.K. Balance of Th1 and Th17 effector and peripheral regulatory T cells. Microbes Infect. (2009) [Electronic publication ahead of Print]
27. Ghilardi N., and Ouyang W. Targeting the development and effector functions of TH17 cells. Semin. Immunol. 19 (2007) 383-393
28. Osorio F., LeibundGut-Landmann S., Lochner M., Lahl K., Sparwasser T., Eberl G., and Reis e Sousa C. DC activated via dectin-1 convert Treg into IL-17 producers. Eur. J. Immunol. 38 (2008) 3274-3281
29. Dörner T., and Radbruch A. Antibodies and B cell memory in viral immunity. Immunity 27 (2007) 384-392
30. Bluestone J.A., and Abbas A.K. Natural versus adaptive regulatory T cells. Nat. Rev., Immunol. 3 (2003) 253-257
31. Bresson D., and von Herrath M. Resuscitating adaptive Tregs with combination therapies?. Novartis Found. Symp. 292 (2008) 50-60 (discussion 60-7, 122-9, 202-3)
32. Reiner S.L. Decision making during the conception and career of CD4+ T cells. Nat. Rev., Immunol. 9 (2009) 81-82
33. Wan Y.Y., and Flavell R.A. Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression. Nature 445 (2007) 766-770
34. Caudy A.A., Reddy S.T., Chatila T., Atkinson J.P., and Verbsky J.W. CD25 deficiency causes an immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like syndrome, and defective IL-10 expression from CD4 lymphocytes. J. Allergy Clin. Immunol. 119 (2007) 482-487
35. Huehn J., Polansky J.K., and Hamann A. Epigenetic control of FOXP3 expression: the key to a stable regulatory T-cell lineage?. Nat. Rev., Immunol. 9 (2009) 83-89
36. Collison L.W., Workman C.J., Kuo T.T., Boyd K., Wang Y., Vignali K.M., Cross R., Sehy D., Blumber R.S., and Vignali D.A. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450 (2007) 556-559
37. Lahl K., Loddenkemper C., Drouin C., Freyer J., Arnason J., Eberl G., Hamann A., Wagner H., and Huehn J. T. Sparwasser. Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease. J. Exp. Med. 204 (2007) 57-63
38. Smyk-Pearson S.K., Bakke A.C., Held P.K., and Wildin R.S. Rescue of the autoimmune scurfy mouse by partial bone marrow transplantation or by injection with T-enriched splenocytes. Clin. Exp. Immunol. 133 (2003) 193-199
39. Lazarski C.A., Chaves F.A., Jenks S.A., Wu S., Richards K.A., Weaver J.M., and Sant A.J. The kinetic stability of MHC class II peptide complexes is a key parameter that dictates immunodominance. Immunity 23 (2005) 29-40
40. Zhang Q., Wang P., Kim Y., Haste-Andersen P., Beaver J., Bourne P.E., Bui H.H., Buus S., Frankild S., Greenbaum J., Lund O., Lundegaard C., Nielsen M., Ponomarenko J., Sette A., Zhu Z., and Peters B. Immune epitope database analysis resource (IEDB-AR). Nucleic Acids Res. 36 (2008) W513-W518
41. Brusic V., Bajic B., and Petrovsky N. Computational methods for prediction of T-cell epitopes-a framework for modelling, testing, and applications. Methods 34 (2004) 436-443
42. De Groot A.S., and Moise L. Prediction of immunogenicity for therapeutic proteins: state of the art. Curr. Opin. Drug Discov. Dev. 10 (2007) 332-334
43. Ahlers J.D., Belyakov I.M., Thomas E.K., and Berzofsky J.A. High-affinity T helper epitope induces complementary helper and APC polarization, increased CTL, and protection against viral infection. J. Clin. Invest. 108 (2001) 1677-1685
44. De Groot A.S., Sbai H., Saint-Aubin C., McMurry J.A., and Martin W. Immuno-informatics: mining genomes for vaccine components. Immunol. Cell Biol. 8 (2002) 255-269
45. Inaba H., Martin W., De Groot A.S., Qin S., and De Groot L.J. Thyrotropin receptor epitopes and their relation to histocompatibility leukocyte antigen-DR molecules in Graves' disease. J. Clin. Endocrinol. Metab. 91 (2006) 2286-2294
46. De Groot A.S., Jesdale B.M., Szu E., Schafer J.R., Chicz R.M., and Deocampo G. An interactive web site providing major histocompatibility ligand predictions: application to HIV research. AIDS Res. Hum. Retrovir. 13 (1997) 529-531
47. Bond K.B., Sriwanthana B., Hodge T.W., De Groot A.S., Mastro T.D., Young N.L., Promadej N., Altman J.D., Limpakarnjanarat K., and McNicholl J.M. An HLA-directed molecular and bioinformatics approach identifies new HLA-A11 HIV-1 subtype E cytotoxic T lymphocyte epitopes in HIV-1-infected Thais. AIDS Res. Hum. Retrovir. 17 (2001) 703-717
48. McMurry J.A., Sbai H., Gennaro M.L., Carter E.J., Martin W., and De Groot A.S. Analyzing Mycobacterium tuberculosis proteomes for candidate vaccine epitopes. Tuberculosis (Edinb.) 85 (2005) 95-105
49. Dong Y., Demaria S., Sun X., Santori F.R., Jesdale B.M., De Groot A.S., Rom W.N., and Bushkin Y. HLA-A2-restricted CD8+-cytotoxic-T-cell responses to novel epitopes in Mycobacterium tuberculosis superoxide dismutase, alanine dehydrogenase, and glutamine synthetase. Infect. Immun. 72 (2004) 2412-2415
50. Koita O.A., Dabitao D., Mahamadou I., Tall M., Dao S., Tounkara A., Guiteye H., Noumsi C., Thiero O., Kone M., Rivera D., McMurry J.A., Martin W., and De Groot A.S. Confirmation of immunogenic consensus sequence HIV-1 T-cell epitopes in Bamako, Mali and Providence, Rhode Island. Hum. Vaccin. 2 (2006) 119-128
51. Panina-Bordignon P., Tan A., Termijtelen A., Demotz S., Corradin G., and Lanzavecchia A. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur. J. Immunol. 19 (1989) 2237-2242
52. Roche P.A., and Cresswell P. High-affinity binding of an influenza hemagglutinin-derived peptide to purified HLA-DR. J. Immunol. 144 (1990) 1849-1856
53. Ferrari C., Bertoletti A., Penna A., Cavalli A., Valli A., Missale G., Pilli M., Fowler P., Giuberti T., Chisari F.V., et al. Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen. J. Clin. Invest. 88 (1991) 214-222
54. Diepolder H.M., Gerlach J.T., Zachoval R., Hoffmann R.M., Jung M.C., Wierenga E.A., Scholz S., Santantonio T., Houghton M., Southwood S., Sette A., and Pape G.R. Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J. Virol. 71 (1997) 6011-6019
55. Kaufmann D.E., Bailey P.M., Sidney J., Wagner B., Norris PJ., Johnston M.N., Cosimi L.A., Addo M.M., Lichterfeld M., Altfeld M., Frahm N., Brander C., Sette A., Walker B.D., and Rosenberg E.S. Comprehensive analysis of human immunodeficiency virus type 1-specific CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides. J. Virol. 78 (2004) 4463-4477
56. L. Moise, M. Ardito, J. Desrosiers, J. Schriewer, M. Buller, S. Frey, S.F. Gregory, S.F. Moss, J. Lee, H. Kornfeld, W. Martin, A.S. De Groot, Immunome-derived Epitope-driven Vaccines (ID-EDV) Protect against Viral or Bacterial Challenge in Humanized Mice. Vaccine (in press) (Electronic publication ahead of print).
57. Roberts C.G.P., Meister G.E., Jesdale B.M., Lieberman J., Berzofsky J.A., and De Groot A.S. Prediction of HIV peptide epitopes by a novel algorithm. AIDS Res. Hum. Retrovir. 12 (1996) 593-610
58. PT-PA-CEFT-001 Data Sheet. Axxora.com. . 2009 May.
59. Tatarewicz S.M., Wei X., Gupta S., Masterman D., Swanson S.J., and Moxness M.S. Development of a maturing T-cell-mediated immune response in patients with idiopathic Parkinson's disease receiving r-metHuGDNF via continuous intraputaminal infusion. J. Clin. Immunol. 27 (2007) 620-627
60. Koren E., De Groot A.S., Jawa V., Beck K.D., Boone T., Rivera D., Li L., Mytych D., Koscec M., Weeraratne D., Swanson S., and Martin W. Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein. Clin. Immunol. 124 (2007) 26-32
61. Barbosa M.D., Vielmetter J., Chu S., Smith D.D., and Jacinto J. Clinical link between MHC class II haplotype and interferon-beta (IFN-beta) immunogenicity. Clin. Immunol. 118 (2006) 42-50
62. Jawa V. Clinical Validation of in silico Prediction of Immunogenicity of a Recombinant Therapeutic Protein, Presentation at the 2nd Protein Therapeutics Discovery and Development Conference, Sept 7-8, 2008, San Diego CA (2008). http://www.gtcbio.com/userAgenda.aspx?id=128 link to abstract available on line at: http://www.gtcbio.com/userAgenda.aspx?id=128
63. Kamperschroer C., Dibble J.P., Meents D.L., Schwartzberg P.L., and Swain S.L. SAP is required for Th cell function and for immunity to influenza. J. Immunol. 177 (2006) 5317-5327
64. McMurry J.A., Johansson B.E., and De Groot A.S. A call to cellular and humoral arms: enlisting cognate T cell help to develop broad-spectrum vaccines against influenza A. Hum. Vaccin. 4 (2008) 148-157
65. Galli G., Medini D., Borgogni E., Zedda L., Bardelli M., Malzone C., Nuti S., Tavarini S., Sammicheli C., Hilbert A.K., Brauer V., Banzhoff A., Rappuoli R., Del Giudice G., and Castellino F. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 3877-3882
66. Chaloupka I., Schuler A., Marschall M., and Meier-Ewert H. Comparative analysis of six European influenza vaccines. Eur. J. Clin. Microbiol. Infect. Dis. 15 (1996) 121-127
67. McMurry J.A., Gregory S.H., Moise L., Rivera D., Buus S., and De Groot A.S. Diversity of Francisella tularensis Schu4 antigens recognized by T lymphocytes after natural infections in humans: identification of candidate epitopes for inclusion in a rationally designed tularemia vaccine. Vaccine. 25 (2007) 3179-3191
68. Celis E., Ou D., and Otvos Jr. L. Recognition of hepatitis B surface antigen by human T lymphocytes. Proliferative and cytotoxic responses to a major antigenic determinant defined by synthetic peptides. J. Immunol. 140 (1998) 1808-1815
69. Min W.P., Kamikawaji N., Mineta M., Tana T., Kashiwagi S., and Sasazuki T. Identification of an epitope for T-cells correlated with antibody response to hepatitis B surface antigen in vaccinated humans. Hum. Immunol. 46 (1996) 93-99
70. Zuckerman J.N. Nonresponse to hepatitis B vaccines and the kinetics of anti-HBs production. J. Med. Virol. 50 (1996) 283-288
71. McDermott A.B., Cohen S.B.A., Zuckerman J.N., and Madrigal J.A. Human leukocyte antigens influence the immune response to a pre-S/S hepatitis B vaccine. Vaccine 17 (1999) 330-339
72. De Groot A.S., Knopf P., and Martin W. De-immunization of therapeutic proteins by T-cell epitope modification. Dev. Biol. (Basel) 122 (2005) 171-194
73. Collen D., Bernaerts R., Declerck P., De Cock F., Demarsin E., Jenné S., Laroche Y., Lijnen H.R., Silence K., and Verstreken M. Recombinant staphylokinase variants with altered immunoreactivity. I: Construction and characterization. Circulation. 94 (1996) 197-206
74. Jones T.D., Phillips W.J., Smith B.J., Bamford C.A., Nayee P.D., Baglin T.P., Gaston J.S., and Baker M.P. Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII. J. Thromb. Haemost. 3 (2005) 991-1000
75. Gilles J.G., Lavend'homme R., Peerlinck K., Jacquemin M.G., Hoylaerts M., Jorieux S., Mazurier C., Vermylen J., and Saint-Remy J.M. Some factor VIII (FVIII) inhibitors recognise a FVIII epitope(s) that is present only on FVIII-vWF complexes. Thromb. Haemost. 82 (1999) 40-45
76. S. Hai, J.A. McMurry, P. Knopf, W. Martin, A.S. De Groot, Immunogenicity screening using in silico methods: Correlation between T-cell epitope content and clinical immunogenicity of monoclonal antibodies. In Therapeutic Antibodies: from Theory to Practice, Zhiqiang An editor. John Wiley and Sons, in press, Scheduled for publication 2009.
77. Hwang W.Y., and Foote J. Immunogenicity of engineered antibodies. Methods 36 (2005) 3-10
78. McIntyre J.A., Kincade M., and Higgins N.G. Detection of IGA anti-OKT3 antibodies in OKT3-treated transplant recipients. Transplantation 61 (1996) 1465-1469
79. Uckun F.M., Messinger Y., Chen C.L., O'Neill K., Myers D.E., Goldman F., Hurvitz C., Casper J.T., and Levine A. Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD19-directed tyrosine kinase inhibitor. Clin. Cancer. Res. 5 (1999) 3906-3913
80. Kaminski M.S., Zelenetz A.D., Press O.W., Saleh M., Leonard J., Fehrenbacher L., Lister T.A., Stagg R.J., Tidmarsh G.F., Kroll S., Wahl R.L., Knox S.J., and Vose J.M. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J. Clin. Oncol. 19 (2001) 3918-3928
81. Stroomer J.W., Roos J.C., Sproll M., Quak J.J., Heider K.H., Wilhelm B.J., Castelijns J.A., Meyer R., Kwakkelstein M.O., Snow G.B., Adolf G.R., and van Dongen G.A. Safety and biodistribution of 99mTechnetium-labeled anti-CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients. Clin. Cancer Res. 6 (2000) 3046-3055
82. McIntyre J.A., Kincade M., and Higgins N.G. Detection of IGA anti-OKT3 antibodies in OKT3-treated transplant recipients. Transplantation 61 (1996) 1465-1469
83. Davis T.A., Grillo-López A.J., White C.A., McLaughlin P., Czuczman M.S., Link B.K., Maloney D.G., Weaver R.L., Rosenberg J., and Levy R. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J. Clin. Oncol. 18 (2000) 3135-3143
84. Piro L.D., White C.A., Grillo-López A.J., Janakiraman N., Saven A., Beck T.M., Varns C., Shuey S., Czuczman M., Lynch J.W., Kolitz J.E., and Jain V. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann. Oncol. 10 (1999) 655-661
85. Pijpe J., van Imhoff G.W., Spijkervet F.K., Roodenburg J.L., Wolbink G.J., Mansour K., Vissink A., Kallenberg C.G., and Bootsma H. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. Arthritis Rheum. 52 (2005) 2740-2750
86. Looney R.J., Anolik J.H., Campbell D., Felgar R.E., Young F., Arend L.J., Sloand J.A., Rosenblatt J., and Sanz I. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 50 (2004) 2580-2589
87. Weinblatt M.E., Maddison P.J., Bulpitt K.J., Hazleman B.L., Urowitz M.B., Sturrock R.D., Coblyn J.S., Maier A.L., Spreen W.R., and Manna V.K. CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose-escalation study. Arthritis Rheum. 38 (1995) 1589-1594
88. Isaacs J.D., Watts R.A., Hazleman B.L., Hale G., Keogan M.T., Cobbold S.P., and Waldmann H. Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet 340 (1992) 748-752
89. Reiff A. A review of Campath in autoimmune disease: biologic therapy in the gray zone between immunosuppression and immunoablation. Hematology 10 (2005) 79-93
90. Radstake T.R., Svenson M., Eijsbouts A.M., van den Hoogen F.H., Enevold C., van Riel P.L., and Bendtzen K. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann. Rheum. Dis. (2008)
91. Bartelds G.M., Wijbrandts C.A., Nurmohamed M.T., Stapel S., Lems W.F., Aarden L., Dijkmans B.A., Tak P.P., and Wolbink G.J. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann. Rheum. Dis. 66 (2007) 921-926
92. Harris J.M., Martin N.E., and Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin. Pharmacokinet. 40 (2001) 539-551
93. Savoca K.V., Abuchowski A., van Es T., Davis F.F., and Palczuk N.C. Preparation of a non-immunogenic arginase by the covalent attachment of polyethylene glycol. Biochim. Biophys. Acta 578 (1979) 47-53
94. Hershfield M.S., Chaffee S., Koro-Johnson L., Mary A., Smith A.A., and Short S.A. Use of site-directed mutagenesis to enhance the epitope-shielding effect of covalent modification of proteins with polyethylene glycol. Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 7185-7189
95. DeGroot A.S. Immunomics: discovering new targets for vaccines and therapeutics. Drug Discov. Today 11 (2006) 203-209